Bristol-Myers Squibb received a double dose of good news this week with two key approvals in Europe. The first is an Opdivo and Yervoy combination for advanced melanoma, the first such immuno-oncology ...
Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results